Elevated serum PSA concentrations have been reported in men with prostate cancer, benign prostatic hypertrophy, and inflammatory conditions of the prostate.
Prostate cancer is the most commonly detected cancer in men in the United States, affecting approximately 1 out of every 6 men. It is the second leading cause of cancer death among men in the United States. Although prostate cancer is thought to begin when men are in their thirties and forties, it is most often diagnosed after age 65. Prevalence increases with age
$26Average competitors price
$59Average competitors price Pricing based on average direct to consumer pricing.
- Fasting Required: NO
- Preferred Specimen: Serum
- Reference Range(s):
Male ≤4.0 ng/mL Female Not established
- Limitations: Based on solid evidence, screening with PSA and/or DRE detects some prostate cancers that would never have caused important clinical problems. Current prostate cancer treatments, including radical prostatectomy and radiation therapy, result in permanent side effects in many men. The most common of these side effects are erectile dystunction and urinary incontinence. Whatever the screening modality, the screening process itself can lead to adverse psychological effects in men who have a prostate biopsy but do not have identified prostate cancer. Prostatic biopsies are associated with complications, including fever, pain, hematospermia/hematuria, positive urine cultures, and rarely sepsis. Lower PSA levels are associated with obesity.
- Turnaround Time: 3 Days
- Test Code: 5363